NasdaqGS:PRAXBiotechs
Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?
Praxis Precision Medicines recently reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while six-month losses reached US$176.28 million with a basic loss per share of US$6.08.
Despite the larger losses, management highlighted continued progress on late-stage central nervous system drug candidates and reiterated that its cash resources are expected to fund operations into 2028, placing near-term...